1.Comparison of Terlipressin and Octreotide with Variceal Ligation for Controlling Acute Esophageal Variceal Bleeding: a Randomized Prospective Study.
Sung Bum CHO ; Kang Jin PARK ; Jung Soo LEE ; Wan Sik LEE ; Chang Hwan PARK ; Young Eun JOO ; Hyun Soo KIM ; Sung Kyu CHOI ; Jong Sun REW ; Sei Jong KIM
The Korean Journal of Hepatology 2006;12(3):385-393
BACKGROUND/AIMS: Terlipressin and octreotide had been used to control acute variceal bleeding and to prevent early rebleeding after endoscopic hemostasis. We compared the efficacy and safety of terlipressin and octreotide combined with endoscopic variceal ligation (EVL) for the treatment of acute esophageal variceal bleeding and we evaluated their clinical significance as related to rebleeding. METHODS: The eighty eight cirrhotic patients were randomized to the terlipressin group (n=43; 2 mg i.v. initially and 1 mg i.v. at every 4 hours for 3 days) or the octreotide group (n=45; continuous infusion of 25 microgram/h for 5 days) combined with EVL for the treatment of acute esophageal variceal bleeding. RESULTS: The initial hemostasis rates were 98% (42/43 cases) in the terlipressin group and 96% (43/45 cases) in the octreotide group. The 5-day and 42-day rebleeding rates were 12% (5/43 cases) and 28% (12/43 cases), respectively, in the terlipressin group and 9% (4/45 cases) and 24% (11/45 cases), respectively, in the octreotide group. No significant difference was demonstrated between the terlipressin and octreotide groups. The mortality at 42 days was similar in both group, but a high mortality rate (48%) was shown to be related to 42-day rebleeding. The risk factors related to 42-day rebleeding were Child-Pugh class C (aOR=30.2, 95% CI=7.7-117.9), ascites above grade II (aOR=6.6, 95% CI=2.2-19.2) and advanced hepatocellular carcinoma (aOR=4.6, 95% CI=1.1-18.9). CONCLUSIONS: Comparing terlipressin and octreotide combined with EVL showed them to be equally safe and effective therapeutic agents in patients with acute esophageal variceal bleeding. The high risk factors related to early rebleeding were poor liver function and advanced hepatocellular carcinoma.
Acute Disease
;
Aged
;
Esophageal and Gastric Varices/drug therapy/surgery/*therapy
;
Female
;
Gastrointestinal Hemorrhage/drug therapy/surgery/*therapy
;
Humans
;
Liver Cirrhosis/drug therapy/surgery/*therapy
;
Lysine Vasopressin/*analogs & derivatives/therapeutic use
;
Male
;
Middle Aged
;
Octreotide/*therapeutic use
;
Vasoconstrictor Agents/*therapeutic use
2.Management of donor liver with fasciolopsiasis for patients with advanced liver cirrhosis.
Zhe-ping FANG ; Zu-chao LIN ; Zheng-lian ZHU ; Shu-sen ZHENG
Chinese Journal of Hepatology 2003;11(4):231-231
Adult
;
Animals
;
Fasciolidae
;
Hepatitis B
;
complications
;
surgery
;
Humans
;
Liver Cirrhosis
;
etiology
;
surgery
;
Liver Transplantation
;
Living Donors
;
Male
;
Trematode Infections
;
drug therapy
3.Fatal Necrotizing Fasciitis Due to Streptococcus pneumoniae: A Case Report.
So Youn PARK ; So Young PARK ; Soo youn MOON ; Jun Seong SON ; Mi Suk LEE
Journal of Korean Medical Science 2011;26(1):131-134
Necrotizing fasciitis is known to be a highly lethal infection of deep-seated subcutaneous tissue and superficial fascia. Reports of necrotizing fasciitis due to Streptococcus pneumoniae are exceedingly rare. We report a case of necrotizing fasciitis in a 62-yr-old man with liver cirrhosis and diabetes mellitus. He presented with painful swelling of left leg and right hand. On the day of admission, compartment syndrome was aggravated and the patient underwent surgical exploration. Intra-operative findings revealed necrotizing fasciitis and cultures of two blood samples and wound aspirates showed S. pneumoniae. The patient died despite debridement and proper antimicrobial treatment. To the best of our knowledge, this is the first case of fatal necrotizing fasciitis with meningitis reported in Korea. We also review and discuss the literature on pneumococcal necrotizing fasciitis.
Anti-Bacterial Agents/therapeutic use
;
Diabetes Mellitus, Type 2/complications/diagnosis
;
Fasciitis, Necrotizing/*diagnosis/drug therapy/microbiology/surgery
;
Fatal Outcome
;
Humans
;
Leg/surgery
;
Liver Cirrhosis/complications/diagnosis
;
Male
;
Middle Aged
;
Streptococcal Infections/*diagnosis/drug therapy
;
Streptococcus pneumoniae/isolation & purification
4.Research Progress in Chinese Medicine Preparations for Promoting Blood Circulation and Removing Blood Stasis for Cirrhotic Patients with Portal Vein Thrombosis Following Splenectomy.
Ding-Qi ZHANG ; Yong-Ping MU ; Ying XU ; Jia-Mei CHEN ; Ping LIU ; Wei LIU
Chinese journal of integrative medicine 2022;28(9):855-863
This article presented an overview of the therapeutic effects of Chinese medicine (CM) preparations for promoting blood circulation and removing blood stasis for patients with portal vein thrombosis (PVT) after splenectomy. Based on published clinical researches of CM preparations for PVT after splenectomy in patients with cirrhotic portal hypertension (CPH), this paper evaluated the incidence of PVT, and explored potential active components and mechanisms of CM preparations. Safflower Yellow Injection, Danshen Injection () Danhong Injection (), and Compound Danshen Dropping Pill () achieved good curative effect alone or combined with anticoagulant therapy. In addition, Compound Biejia Ruangan Tablet () and Anluo Huaxian Pill () can also significantly improve the hemodynamic disorders of portal vein system in patients with cirrhosis. Considering the role of CM preparations in ameliorating the incidence of PVT after splenectomy in patients with CPH, we suggested that future research should provide more attention to CM alone or CM combined with anticoagulant for cirrhosis with PVT.
Anticoagulants/therapeutic use*
;
Humans
;
Hypertension, Portal/drug therapy*
;
Liver Cirrhosis/surgery*
;
Medicine, Chinese Traditional/adverse effects*
;
Portal Vein
;
Risk Factors
;
Splenectomy/adverse effects*
;
Venous Thrombosis/etiology*
5.A report from the Chinese National Fourteenth Symposium on Viral Hepatitis and Liver Diseases.
Chinese Journal of Hepatology 2009;17(8):636-637
Antiviral Agents
;
pharmacology
;
therapeutic use
;
Congresses as Topic
;
Drug Resistance, Viral
;
Hepatitis B, Chronic
;
diagnosis
;
drug therapy
;
virology
;
Hepatitis C, Chronic
;
diagnosis
;
drug therapy
;
virology
;
Humans
;
Liver Cirrhosis
;
diagnosis
;
therapy
;
Liver Failure
;
prevention & control
;
Liver Neoplasms
;
surgery
;
therapy
;
Nucleosides
;
pharmacology
;
therapeutic use
6.Decorin accelerates the liver regeneration after partial hepatectomy in fibrotic mice.
Rui MA ; Jiang CHEN ; Zheyong LI ; Jiacheng TANG ; Yifan WANG ; Xiujun CAI ;
Chinese Medical Journal 2014;127(14):2679-2685
BACKGROUNDConsidering the existence of a large number of liver cell degeneration and necrosis in fibrotic liver, liver function was damaged severely and could not effectively regenerate after partial hepatectomy (PHx). The aim of this study was to investigate whether decorin (DCN) could promote the liver regeneration after PHx in fibrotic mice.
METHODSForty mice (5-week-old, Balb/c) were injected with CCl4 intraperitoneally and liver fibrosis model was established after 5 weeks. The survival mice were randomly divided into two groups: control group and DCN group. Then, we performed 70% PHx on all these mice and injected DCN or phosphate-buffered saline plus normal saline (NS) to each group, respectively, after surgery. Liver body weight ratio (LBR), quantitative real-time polymerase chain reaction, and immunohistochemistry were used to analyze liver regeneration and fibrosis degree in both groups, and to find out whether exogenous protein DCN could promote the regeneration of fibrosis liver after PHx.
RESULTSExpressions of a-smooth muscle actin (SMA) mRNA and LBR had significant increases in the DCN group at postoperative Day 3 (POD 3, P < 0.05). The protein expressions of CD31, a-SMA, and tumor necrosis factor (TNF)-a were higher in the DCN group than those in the control group by immunohistochemistry at POD 3 (P < 0.05).
CONCLUSIONExogenous protein DCN could promote liver regeneration after PHx in fibrotic mice.
Animals ; Decorin ; therapeutic use ; Hepatectomy ; Immunohistochemistry ; Liver Cirrhosis ; drug therapy ; metabolism ; surgery ; Liver Regeneration ; drug effects ; Male ; Mice ; Mice, Inbred BALB C ; Platelet Endothelial Cell Adhesion Molecule-1 ; metabolism
7.Effects of hepatotrophic factors on the liver after portacaval shunt in rats with portal hypertension.
Zhong-tao ZHANG ; Peng JIANG ; Yu WANG ; Jian-She LI ; Jian-guo XUE ; Yan-zhong ZHOU ; Zhu YUAN
Chinese Medical Journal 2006;119(20):1727-1733
BACKGROUNDPortacaval shunt (PCS) prevent hepatotrophic factors from flowing into the liver, but they enter directly the systemic circulation and worsen liver injury. This study was designed to investigate the effects of hepatotrophic factors through the portal vein on the liver in rats with portal hypertension after portacaval shunt.
METHODSIntrahepatic portal hypertension (IHPH) was induced by intragastric administration of carbon tetrachloride, and end-to-side PCS was performed. Eight normal rats served as controls, and eight rats with IHPH served as IHPH model (IHPH group). Another 32 rats with IHPH-PCS were randomly subdivided into 4 groups: normal saline (NS) given to 8 rats, hepatocyte growth factor (HGF) 8, insulin (INS) 8, hepatocyte growth factor and insulin (HGF + INS) 8. Hepatotrophic factors were infused into the portal vein through an intravenous catheter. Portal venous pressure (PVP) was measured. The levels of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were tested biochemically and those of hyaluronic acid (HA) and laminin (LN) were measured by radioimmunoassay. Hepatic fibrosis was assessed histologically and the expression of collagens type I and III were detected immunohistochemically. Ultrastructural change of hepatocytes and the number of mitochondria were observed under an electron microscope. The data were compared between groups and subgroups by Student-Newman-Keuls procedure with SPSS10.0.
RESULTSPVP was significantly higher in the IHPH rats than in the control rats (P < 0.05). The levels of serum ALT, AST, HA, and LN, hepatic fibrosis score, the amount of collagen deposition, collagens type I and III increased more significantly in the IHPH group than in the control rats (P < 0.05). The number of mitochondria decreased more significantly in the IHPH rats than in the control rats (P < 0.05). The levels of serum ALT, AST, HA and LN as well as hepatic fibrosis score, the amount of collagen deposition, and the amount of collagens type I and III in the HGF and HGF + INS rats were significantly lower than those in the NS rats (P < 0.05). The damage to hepatocyte ultrastructure was markedly alleviated and the number of mitochondria was increased more significantly in the HGF and HGF + INS rats than in the NS rats under an electron microscope.
CONCLUSIONSPerfusion of exogenous hepatotrophic factors through the portal vein can alleviate liver injury, minimize the damage to the ultrastructure of hepatocyte, protect liver function, and lessen hepatic fibrosis in rats with portal hypertension after PCS.
Alanine Transaminase ; blood ; Animals ; Aspartate Aminotransferases ; blood ; Extracellular Matrix ; metabolism ; Hepatocyte Growth Factor ; pharmacology ; Hypertension, Portal ; metabolism ; pathology ; surgery ; Insulin ; pharmacology ; Liver ; drug effects ; pathology ; ultrastructure ; Liver Cirrhosis, Experimental ; drug therapy ; Male ; Portacaval Shunt, Surgical ; Rats ; Rats, Sprague-Dawley
8.Comparison of endoscopic band ligation and propranolol for the primary prophylaxis of variceal bleeding in cirrhosis.
Chao FENG ; Feizhou HUANG ; Wanpin NIE ; Xunyang LIU ; Shuping REN
Journal of Central South University(Medical Sciences) 2012;37(5):513-516
OBJECTIVE:
To compare endoscopic variceal ligation (EVL) with propranolol for prophylaxis of first variceal bleeding.
METHODS:
We chose 168 patients with cirrhosis and esophageal varices in our hospital and allocated them to EVL and propranolol groups. Treatment effectiveness and safety in the 2 groups were observed.
RESULTS:
he parameters of two groups were similar before therapy. Follow-up period was 8-36 months. Variceal bleeding occurred in 24 (28.6%) of the EVL group and in 20 (23.9%) of the propranolol group (P>0.05). Overall mortality and death related to bleeding were similar (21.4% vs 17.9%; 7.1% vs 6.0%, P>0.05). Adverse events related to EVL were 43 (3 of them life-threatening) compared to 16 in the propranolol group (51.19% vs 19.05%, P<0.05).
CONCLUSION
Propranolol may be the better choice in prophylaxis of variceal bleeding with similar effects and lower adverse events than with EVL.
Aged
;
Endoscopy, Gastrointestinal
;
methods
;
Esophageal and Gastric Varices
;
complications
;
drug therapy
;
surgery
;
therapy
;
Female
;
Gastrointestinal Hemorrhage
;
etiology
;
prevention & control
;
Humans
;
Ligation
;
methods
;
Liver Cirrhosis
;
complications
;
Male
;
Middle Aged
;
Propranolol
;
therapeutic use
9.Type 2 Hepatorenal Syndrome in a Cirrhotic Patient Who Underwent Gastric Cancer Surgery.
The Korean Journal of Gastroenterology 2010;56(3):125-127
No abstract available.
Adult
;
Hepatitis C/diagnosis
;
Hepatorenal Syndrome/*diagnosis/drug therapy/surgery
;
Humans
;
Liver Cirrhosis/*diagnosis
;
Lypressin/analogs & derivatives/therapeutic use
;
Male
;
Portasystemic Shunt, Transjugular Intrahepatic
;
Stomach Neoplasms/*surgery
;
Tomography, X-Ray Computed
;
Vasoconstrictor Agents/therapeutic use
10.Clinical Outcome after Living Donor Liver Transplantation in Patients with Hepatitis C Virus-associated Cirrhosis.
Jeong Ik PARK ; Kun Moo CHOI ; Sung Gyu LEE ; Shin HWANG ; Ki Hun KIM ; Chul Soo AHN ; Deok Bog MOON ; Young Hwa CHUNG ; Yung Sang LEE ; Dong Jin SUH
The Korean Journal of Hepatology 2007;13(4):543-555
BACKGROUND AND AIMS: Hepatitis C virus (HCV)-associated cirrhosis is an increasingly frequent indication for liver transplantation (LT). However, HCV recurrence is universal and this immediately occurs following LT, which endangers both the graft and patient survival. We investigated the frequency of posttransplant recurrence of HCV infection and the patient-graft survival, and we analyzed the responses to ribavirin and interferon therapy in the patients with recurrent HCV infection after living donor liver transplantation (LDLT). METHODS: We retrospectively reviewed the clinical outcomes of 39 HCV-associated cirrhosis patients who underwent LDLT at Asan Medical Center between August 1992 and June 2006. In this study, the diagnosis of recurrent HCV was made on the basis of increased transaminases and serum HCV RNA levels greater than 10 million IU/mL because protocol liver biopsy was not performed. RESULTS: HCV recurrence was seen in 26 of the 39 LDLT patients (66.7%). 86.7% of recurrence occurred within the first postoperative year. Antiviral treatment was used for all patients with recurrence of HCV. None of the 10 patients receiving ribavirin alone and 9 of 16 patients who received combination therapy with pegylated interferon alpha-2a plus ribavirin became HCV RNA negative and they remained persistently negative during the median follow-up of 24.9 months. Our data indicates that there is no significant factor influencing HCV recurrence except for the recipient's age. The 2-year patient survival for the HCV patients with HCC and those patients without HCC were 81.2% and 81.3%, respectively (P=0.85) and the 2-year graft survival rates were 81.2% and 68.2%, respectively (P=0.29). No patient died from HCV recurrence during the follow-up period. CONCLUSIONS: Combination therapy with ribavirin and interferon appears to improve the outcome of recurrent HCV infected patients after LDLT.
Adult
;
Aged
;
Antiviral Agents/therapeutic use
;
Combined Modality Therapy
;
Female
;
Graft Survival
;
Hepacivirus/drug effects/isolation & purification
;
Hepatitis C, Chronic/complications/diagnosis/*drug therapy
;
Humans
;
Interferon Alfa-2a/therapeutic use
;
Liver Cirrhosis/mortality/*surgery/*virology
;
Liver Neoplasms/mortality
;
*Liver Transplantation
;
Living Donors
;
Male
;
Middle Aged
;
Polyethylene Glycols/therapeutic use
;
Recurrence
;
Retrospective Studies
;
Ribavirin/therapeutic use
;
Severity of Illness Index
;
Treatment Outcome